Marcio Souza
CIK 1707657 · Chief Executive Officer · last filed 2026-07-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$24.02M
Companies
3
Total Filings
42
Lifetime Open-Market Net
-$5.06M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRAX | Chief Executive Officer | 56,495 | $353.44 | $19.97M | $371.8K | 28 | 2026-07-08 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | 3,600 | $12.01 | $43.2K | $50.5K | 3 | 2022-08-25 |
| PTCT | Chief Operating Officer | 57,466 | $70.56 | $4.05M | -$5.48M | 11 | 2020-02-12 |
Recent Filings · Page 3 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-08-25 | Spyre Therapeutics, Inc. (AGLE) Delisted | Buy (P) | +90,000 | $50.5K | EDGAR |
| 2022-06-24 | PRAX | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | PRAX | Buy (P) | +27,000 | $49.9K | EDGAR |
| 2022-06-09 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-18 | PRAX | Grant (A) | +1,392 | $12.2K | EDGAR |
| 2022-01-11 | PRAX | Grant (A) | +74,000 | $0 | EDGAR |
| 2021-08-19 | PRAX | Buy (P) | +9,542 | $150.7K | EDGAR |
| 2021-06-22 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-17 | PRAX | Grant (A) | +52,800 | $0 | EDGAR |
| 2020-11-10 | PRAX | Buy (P) | +3,846 | $100.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.